Fredun Pharmaceuticals Ltd (BSE: 539730) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,263 Cr, it ranks #1,151 by market cap among the 6,189 Indian listed companies on FinBizNet, and #36 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,368.10 (as of 26 Oct 2026), the share price is 17.8% below its 52-week high of ₹1,665.00 and 14.5% above its 52-week low of ₹1,195.20. The share price is up 238.8% over one year and up 67.4% over three months.
| Current Price | ₹1,368.10 |
|---|---|
| Market Cap | ₹2,263 Cr |
| BSE Code | 539730 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 67 |
| Return on Equity | 15.55% |
| Return on Assets | 9.14% |
| 52-Week Range | ₹1,195.20 – ₹1,665.00 |
| 1-Year Price Change | +238.8% |
| 3-Month Price Change | +67.4% |
| Beta (1Y) | 0.54 |
| Dividend Yield | 0.02% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.fredungroup.com |
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, anti-bacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelmintic, antibacterial, analgesics, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, anticoagulants, anticonvulsants, antidiarrhoeal, antidepressant, antifungal, antihistamines/antiallergic, antihypertensives, antiviral, bone modulating drugs, bronchodilators and anti-asthma drugs, calcium tablets, cardiovascular, diuretic, impotence drugs, laxative, and appetite stimulant with multivitamins. It also provides surgical products, such as IV fluids and cannula, disposable syringes, infusion sets, surgical gloves and
1. Pharmaceutical Formulations-This segment manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, and other healthcare products. It also provides animal healthcare products, as well as allopathic formulations and on field diagnostic kits.
1. Pharmaceutical and Healthcare-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | 36.6 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | 22.5 | 18.32% | ₹8,017 Cr | +14.7% |
| Cipla Limited | ₹1,08,090 Cr | 27.9 | 11.74% | ₹7,119 Cr | -14.7% |
| Laurus Labs Ltd | ₹1,06,442 Cr | 119.8 | 17.74% | ₹2,026 Cr | +125.7% |
| Dr.Reddys Lab | ₹1,02,010 Cr | 23.8 | 11.52% | ₹8,698 Cr | -0.9% |
| Mankind Pharma | ₹91,379 Cr | 47.8 | 12.45% | ₹4,031 Cr | -9.9% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | 26 | 9.93% | ₹9,150 Cr | +41.7% |
| Lupin Ltd | ₹88,018 Cr | 16.5 | 26.91% | ₹8,277 Cr | -1.1% |
| Fredun Pharmaceuticals Ltd | ₹2,263 Cr | 67 | 15.55% | — | +238.8% |
Listed by market capitalisation. Ratios are shown for context only.
Fredun Pharmaceuticals Ltd is trading at ₹1,368.10, with a market capitalisation of ₹2,263 Cr.
Fredun Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Fredun Pharmaceuticals Ltd has a P/E of 67 and a return on equity of 15.55%.
Fredun Pharmaceuticals Ltd is listed on the BSE under the scrip code 539730.
Fredun Pharmaceuticals Ltd's share price is up 238.8% over one year and up 67.4% over three months. Its 52-week range is ₹1,195.20 to ₹1,665.00.
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.